Benzinga Pro
Marketfy
Financial Data & APIs
Events
Premarket Prep
Membership is Free
What are you waiting for? Sign up now!
Name:
Username available!
Username taken!
Email:
Email available!
Email taken!
Password:
Leave blank:
OR
Free Account Login
Click here to access your premium account
Username or email:
Password:
OR
Forgot password?
Contribute
Login
Join
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Retail Sales
Offerings
IPOs
Insider Trades
Biotech/FDA
Freight
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
Global Economics
Previews
Reviews
Small-Cap
Cryptocurrency
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Tech
Start-Ups
Fintech
Investing
Best Online Brokers
Personal Finance
Compare Brokers
Interactive Brokers Review
TD Ameritrade Review
Ally Invest Review
Etrade Review
Personal Capital Review
Tradestation Review
Forex.com Review
Binary Options Review
Suretrader Review
Premium
Market Overview
Tickers
Articles
Keywords
Search by keyword...
googlecse
WANT TO CATCH
SCLN
NEWS
BEFORE
IT CHANGES THE STOCK PRICE?
More From
Summary
Ideas
Twitter ($)
All News
Analyst Coverage
Analyst Ratings
News Coverage
News
General
Contracts
Dividend Summaries
Dividend Calendar
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Press Releases
Earnings
Earning Summaries
Earnings Calendar
Guidance Summaries
SciClone Pharmaceuticals, Inc.
:
Add to Watchlist +
{{ portfolio.portfolio_name }}
You have no watchlists at this time, click "Manage watchlists" to create your first watchlist.
Manage watchlists
Sector:
Industry:
0.0000
0 (%)
Data as of Jan 16, 2019
Prev. Close
Price Open
Volume
0
Day's Range
-
52 Wk Range
-
50 Day Moving Avg.
PE Ratio
Shares Outstanding
Market Cap
Trade SCLN stock with
recommended broker Ally Invest
. Commissions as low as $3.95.
1d
5d
1m
3m
1y
5y
YTD
Analyst Rating
View All Ratings
Date
Research Firm
Action
Current
Target
11/29/16
Maxim Group
Initiates Coverage On
Buy
6/29/15
MLV & Co.
Initiates Coverage on
Buy
15.0
11/14/14
BWS Financial
Downgrades
Buy
Hold
Headlines
Press Releases
33 Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
Thu, 12 Oct 2017 11:40:16 -0500
S&P Dow Jones Indices Reports 'NMI Holdings and Axcelis Technologies Set to Join S&P SmallCap 600'
Paul Quintaro
Wed, 11 Oct 2017 16:18:15 -0500
SciClone Reports Q2 Adj. EPS $0.30 vs $0.24 Est., Sales $44.5M vs $43.4M Est.
Paul Quintaro
Wed, 09 Aug 2017 15:29:20 -0500
Wall Street's M&A Chatter From June 8: Cabelas, SciClone Pharma, Microsoft-Hexadite, Athenahealth-Praxify
Charles Gross
Fri, 09 Jun 2017 05:51:25 -0500
15 Biggest Mid-Day Gainers For Thursday
Lisa Levin
Thu, 08 Jun 2017 11:28:55 -0500
22 Stocks Moving In Thursday's Pre-Market Session
Lisa Levin
Thu, 08 Jun 2017 07:07:58 -0500
A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Jobless Claims
Lisa Levin
Thu, 08 Jun 2017 06:28:10 -0500
SciClone Pharma to be Acquired by GL Capital for $11.18/Share Cash
Paul Quintaro
Thu, 08 Jun 2017 05:01:50 -0500
SciClone Reports Q1 Adj. EPS $0.31 vs $0.14 Est., Sales $42.9M vs $39.9M Est.
Paul Quintaro
Wed, 10 May 2017 15:46:15 -0500
20 Stocks Moving In Monday's Pre-Market Session
Lisa Levin
Mon, 17 Apr 2017 07:24:04 -0500
{{ story.title }}
{{ story.author }}
{{ story.created }}
Show more
Loading articles...
Consortium Led By GL Capital Completes Acquisition Of SciClone
PRNewswire
Oct 13, 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SciClone Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 30, 2017
Business Wire
Aug 29, 2017
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of SciClone Pharmaceuticals, Inc. - SCLN
PRNewswire
Aug 17, 2017
SciClone Announces End Of Go-Shop Period With No Parties Designated As Excluded Parties
PRNewswire
Aug 10, 2017
SciClone Reports Second Quarter 2017 Financial Results
PRNewswire
Aug 09, 2017
INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of SciClone Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information
Business Wire
Jun 19, 2017
SCICLONE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SciClone Pharmaceuticals, Inc.
PRNewswire
Jun 19, 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of SciClone Pharmaceuticals Inc. to a Consortium is Fair to Shareholders
Business Wire
Jun 15, 2017
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of SciClone Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information
Business Wire
Jun 13, 2017
SCICLONE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
Business Wire
Jun 13, 2017
{{ story.title }}
{{ story.author }}
{{ story.created }}
Show more
Loading articles...
Partner Headlines
Stonepine Capital Management, LLC Buys Viveve Medical Inc, Avadel Pharmaceuticals PLC, ...
GuruFocus
May 15, 2017
SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q4 2016 Results - Earnings Call Transcript
Seeking Alpha
Mar 06, 2017
SciClone Pharmaceuticals reports Q4 results
Seeking Alpha
Mar 06, 2017
SciClone Pharmaceuticals: Beyond The Death Of A Sales Process
Seeking Alpha
Feb 02, 2017
Adds and drops from the Nasdaq Biotech Index
Seeking Alpha
Dec 13, 2016
Week In Review: Week's China Life Science Deals Total $795 Million
Seeking Alpha
Nov 20, 2016
SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q3 2016 Results - Earnings Call Transcript
Seeking Alpha
Nov 11, 2016
SciClone Pharmaceuticals reports Q3 results
Seeking Alpha
Nov 09, 2016
Valuation Dashboard: Healthcare - Update
Seeking Alpha
Nov 09, 2016
Week In Review: Big Week For Cross-Border Life Science Deals
Seeking Alpha
Oct 02, 2016
{{ story.title }}
{{ story.author }}
{{ story.created }}
Show more
Loading articles...
Earnings
View Earnings
Q2 2017
EST
Actual
Surprise
EPS:
0.24
0.3
0.06
Rev:
43.44M
44.52M
1.08M
EST
Actual
Surprise
EPS:
Expected
Rev:
WILL
SCLN
SPIKE ON TOMORROW'S NEWS?
Stocks like
SCLN
are creating awesome opportunities based on catalysts in the news. Is
SCLN
the next one to get some major price action?
Create a Benzinga Pro account today to find out.
Brokerage Center
Compare All Online Brokerages
Benzinga - Feed Your Mind
try pro
News
Markets
Ratings
Ideas
Tech
Small-Cap
Personal Finance
Premium Products
